Research Analysis Platform 2.0

Description

UK Biobank ("UKB") currently hosts a cloud-based health Research Analysis Platform which makes research projects and data accessible to researchers ("RAP"). The current RAP was procured by UKB in 2020 and was developed by DNAnexus, in collaboration with, and cloud infrastructure provided by, Amazon Web Services. UKB intends to initiate a procurement exercise in 2026 for the development of a new RAP ("RAP2.0") to take account of advances in technology over the past 5 years and its future requirements. The RAP2.0 is anticipated to be the default way that most researchers will access and analyse UKB's biomedical database and it is anticipated to comprise one or more software platforms or data analysis services that work together to meet the diverse functional needs to the research community. UKB currently intends to undertake separate procurements in relation to (i) the RAP2.0, (ii) cloud infrastructure, and (iii) automated airlock software to control extraction of data held by UKB for research purposes, whilst ensuring the ongoing security and confidentiality of the data and confidentiality of the data. UKB has established an informatics working group consisting of senior experts who will provide guidance to help develop the requirements for the technology listed at (i) - (iii) above. It is currently envisaged that the first procurement to be undertaken will relate to the cloud infrastructure (in late 2025/early 2026), followed by the procurement of the RAP2.0 in 2026. The procurement of the airlock software may be conducted in parallel to, or follow sequentially, (i) and/or (ii). This Preliminary Market Engagement Notice relates to the development of the RAP2.0. Separate Preliminary Market Engagement Notices are being published for cloud infrastructure and airlock software.

Links & Documents

About UK BIOBANK LIMITED

Published contracts in the last 12 months

Similar contracts